Dobutamine tartrate
Based on 5 publication(s) in Google Scholar
Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion.
For research use only. We do not sell to patients.
- CAS No.: 101626-66-8
- Formula: C22H29NO9
- Molecular Weight:451.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dobutamine tartrate
More
Customer Validation & Images
-
Apoptosis Analysis
-
Flow Cytometry
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
IF
All Adrenergic Receptor Isoforms
More
Biological Activity
|
α adrenergic receptor |
β adrenergic receptor |
Dobutamine tartrate (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice[3].
Dobutamine tartrate results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice[3].
Low doses of Dobutamine tartrate significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice[3].
Dobutamine tartrate increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost[3].
Dobutamine tartrate increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tgαq*44 mice (heart failure models)[3]
-
Dosage:0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose
-
Administration:Intraperitoneal injection
-
Result:Induced different response in cardiac function on a low and high dose in mice with with heart failure.
Chemical Information
-
CAS No. 101626-66-8
-
Molecular Weight 451.47
-
Formula C22H29NO9
-
SMILES
OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O.O=C(O)[C@@H](O)[C@H](O)C(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
2025 Jul 15;97(27):14220-14229. PMID: 40601392 -
Biochem Pharmacol
2025 Nov 29:244:117576. PMID: 41319924 -
Front Cell Dev Biol
2022 Apr 20;10:889656. PMID: 35517499
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-downcells with IR treatment.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) showed the percentages of G1 cells in IRtreated control and BRCA1 knock-down A2780 cells decreased to 44.32 and 43.03%, respectively, suggesting that cAMP terminated the cell cycle arrest caused by DNA damage. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM) treated BRCA1 knock-down A2780 cells could inhibited the proliferation of the CD8+ T cells.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) showed weaker BAX signals in the IR-irradiated control and BRCA1 knockdown A2780 cells, and 13.7 and 14.5% of cancer cells were BAX positive, respectively.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of BAX and cleaved caspase-3 in the IR-irradiated control and BRCA1 knockdown A2780 cells.
Dobutamine tartrate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]
Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of p53 in the IR-irradiated BRCA1 knockdown A2780 cells.
-
Comput Struct Biotechnol J
Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor. [Abstract]2023 Jul 7:21:3490-3502. PMID: 37484490 -
Environ Toxicol
Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor. [Abstract]2024 Mar;39(3):1682-1699. PMID: 38041472
Purity & Documentation
References
[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96. [Content Brief]
[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402. [Content Brief]
[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77. [Content Brief]
[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dobutamine tartrate Related Classifications
HY-15746B Related Classifications
Powered by Bioz